Enliven Therapeutics
ELVN
35 hedge funds and large institutions have $74.5M invested in Enliven Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 11 closing their positions.
1,622% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $77K
297% more capital invested
Capital invested by funds: $18.8M → $74.5M (+$55.7M)
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
13% more funds holding
Funds holding: 31 → 35 (+4)
9.5% more ownership
Funds ownership: 7.83% → 17.33% (+9.5%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$13M |
| 2 |
CC
Commodore Capital
New York
|
+$9.97M |
| 3 |
Janus Henderson Group
London,
|
+$3.71M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.72M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$2.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.92M |
| 2 |
Renaissance Technologies
New York
|
-$462K |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$388K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$372K |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
-$226K |
ELVN Hedge Fund Activity: Q4 2022 in Review
35 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q4 2022, worth a combined $74.5M — up 297% from $18.8M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ELVN positions and 11 closed out — a net gain of 6 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $13M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $1.92M sold.
- 35 institutional investors held Enliven Therapeutics (ELVN) as of Q4 2022, up from 31 in Q3 2022.
- Funds reported $74.5M of Enliven Therapeutics stock for Q4 2022, up 297% quarter-over-quarter.
- 17 funds opened new Enliven Therapeutics positions in Q4 2022 and 11 closed out, a net change of +6 holders.
- The largest Enliven Therapeutics buyer in Q4 2022 was RA Capital Management, an estimated $13M added.
- The largest Enliven Therapeutics seller in Q4 2022 was Rock Springs Capital Management, an estimated $1.92M sold.
Based on aggregated 13F filings for Q4 2022.